Cytodyn Inc Dr. Nader Pourhassan, CytoDyn's CEO, Addresses The False Claims Made By STAT News Transcript
Hello, and welcome back to Proactive New York. I'm Christine Corrado. With me right now is Nader Pourhassan, CEO at CytoDyn. Nader, great to see you. How are you?
I am doing great. It's a beautiful day and thank you for having me.
Nader, a lot to get to today. First off, you announced positive coronavirus clinical trial results on your shareholders' call meeting yesterday. However, a report came out from a healthcare publication called STAT, suggesting that your description of CytoDyn's leronlimab data points hasn't met its goal in treating coronavirus patients. What's your response to that?
So our goal is to create data that FDA gets to see and have FDA make a decision on those. We don't pay attention to this kind of false report usually. But we are an OTC company, and we have an obligation to refuse the statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
